Clinical Trial Search

Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…

Primary: The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the…

Primary: Number of Subjects With Combined Clinical and Microbiologic Response — 70 Participants

Primary: Number of Participants With Overall Success — 36; 17 Participants

Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…

Primary: Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT)…

Primary: Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit — 19; 25 Participants

Primary: Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success — 62.6; 36.0 percentage of participants

Primary: Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test — 276; 276; 103; 124 Participants

Primary: Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test — 276; 276; 103; 124 Participants

Primary: Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure — 72.6; 54.6 percentage of participants

Primary: Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population — 50…

Primary: Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC) — 80.7 Percentage of participants

Primary: Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) Population — 207; 83 Participants — p=0.0088

Primary: Microbiological Response Assessment Profile — 58; 63 Participants

Primary: Favorable Clinical Outcomes (FCl) — 170; 132 Participants

Primary: Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population — 83.1; 76.3 percentage of patients

Primary: Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI) — 7; 6 Participants

Primary: Clinical Cure — 140; 123; 10; 27 participants

Primary: Post-operative Urinary Tract Infection — 19; 20 Participants

Primary: Number of Participants Experiencing Urinary Tract Infection Within 6 Weeks of Surgery — 13; 13 Participants — p=0.97

Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant

Primary: Percentage of Participants With Overall Success — 301; 325 Participants

Primary: Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the Microbiological Modified ITT (mMITT) Population at Day 5 — 88; 91.4; 10.5…

Primary: Participants In The Microbiological Intent-To-Treat (Micro-ITT) Population With A Responder Outcome At The Post-Treatment (PT) Visit — 180; 202; 100; 91 Participants

Primary: Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI Visit — 363; 382; 51; 7 Participants

Primary: Percentage of Subjects With Overall Success at Test-of-Cure — 250; 93; 31; 43 Participants

Primary: Percentage of Participants With a Favorable Microbiological Response at Completion of IV Study Therapy — 95.5; 98.6; 98.7 Percentage of Participants — p=0.005

Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001

Primary: Clinical Validation of Biosensor Assays Used for Pathogen Identification and Antimicrobial Susceptibility Testing in Patients at Risk of Urinary Tract Infections. — 89…